Exploring the unexplored avenues of surface charge in nano-medicine
Source abstract
Abstract
Abstract Electrostatic interactions include weak attractive and repulsive interactions based on the magnitude and polarity of the charge the particle possess. These charges could play a substantial role if the concept of electrostatic interaction is applied in the field of nano-medicine. Surface charge is one of the most important armament of a researcher in the field of drug delivery. However, in recent times, not much attention has been paid to its attributes. Surface charge influences several processes like stability, drug delivery, cytotoxicity, bio-distribution, cell uptake, permeation of biological barriers, etc. This review highlights the importance of surface charge at the cellular and molecular level. We also emphasize on how a researcher can use surface charge to advance the current delivery systems in various desired applications.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. How electrostatic and non-electrostatic interactions play a role in water wettability of possible nanostructure surfaces10.1007/s40097-019-00329-6 ↗
2. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells
3. Polymeric siRNA gene delivery – transfection efficiency versus cytotoxicity10.1016/j.jconrel.2019.10.046 ↗
4. Surface protein engineering increases the circulation time of a cell membrane-based nanotherapeutic10.1016/j.nano.2019.02.024 ↗
5. Engineering the drug carrier biointerface to overcome biological barriers to drug delivery10.1016/j.addr.2020.06.007 ↗
6. Nanoparticle surface functionality dictates cellular and systemic toxicity10.1021/acs.chemmater.7b01979 ↗
7. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles10.1016/j.ijpharm.2005.10.010 ↗
8. Effects of surface charge of hyperbranched polymers on cytotoxicity, dynamic cellular uptake and localization, hemotoxicity, and pharmacokinetics in mice10.1021/acs.molpharmaceut.7b00611 ↗
9. Physiological, biochemical, and chemical barriers to oral drug delivery
10. Application of validated protocols to characterize size and zeta potential of dispersed materials using light scattering methods10.1016/j.colsurfa.2018.09.006 ↗
11. Zeta potential measurements for non-spherical colloidal particles – practical issues of characterisation of interfacial properties of nanoparticles10.1016/j.colsurfa.2017.04.010 ↗
12. DLS and zeta potential - what they are and what they are not?10.1016/j.jconrel.2016.06.017 ↗
13. Ostwald ripening of confined nanoparticles: chemomechanical coupling in nanopores10.1039/C9NR01349K ↗
14. Formation of nanosuspensions in bottom-up approach: theories and optimization, DARU
15. Electronic and steric control of n→π* interactions: stabilization of the α-helix conformation without a hydrogen bond10.1002/cbic.201800785 ↗
16. Steric stabilization of RIPL peptide-conjugated liposomes and in vitro assessment10.1007/s40005-018-0392-6 ↗
17. Surface complexation modeling of calcite zeta potential measurements in brines with mixed potential determining ions (Ca2+, CO32−, Mg2+, SO42−) for characterizing carbonate wettability10.1016/j.jcis.2017.06.096 ↗
18. Efficient preparation of size tunable PEGylated gold nanoparticles10.1039/C6TB00886K ↗
19. Disperse systems: suspensions
20. Suspensions of iron oxide nanoparticles stabilized by anionic surfactants10.1007/s11743-012-1425-1 ↗
21. Lipid nanoparticulate systems
22. Non-lamellar lyotropic liquid crystalline lipid nanoparticles for the next generation of nanomedicine10.1021/acsnano.8b07961 ↗
23. Nanoparticle decoration with surfactants: molecular interactions, assembly, and applications10.1016/j.surfrep.2017.02.001 ↗
24. Feasibility of electrostatic-mediated post-functionalization to induce long term colloidal stability and stability after freeze drying of amphoteric nanoparticles10.1016/j.colcom.2018.02.003 ↗
25. Zwitterionic amphiphiles: their aggregation behavior and applications10.1039/C9GC01808E ↗
26. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability10.1208/s12249-019-1524-7 ↗
27. Steric stabilization of phycobiliprotein loaded liposome through polyethylene glycol adsorbed cellulose nanocrystals and their impact on the gastrointestinal tract10.1016/j.foodhyd.2019.105252 ↗
28. Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery10.2174/1381612822666161010111741 ↗
29. Lipid-based nanosystem as intelligent carriers for versatile drug delivery applications10.2174/1381612826666200206094529 ↗
30. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles10.1016/j.colsurfb.2011.02.033 ↗
31. Polymer colloids as drug delivery systems for the treatment of arthritis10.1016/j.cis.2020.102273 ↗
32. Drug release patterns and cytotoxicity of PEG-poly(aspartate) block copolymer micelles in cancer cells10.1007/s11095-012-0697-5 ↗
33. A series of codendrimers from polyamidoamine (PAMAM) and oligoethylene glycols (OEG) dendrons as drug carriers: the effect of OEG dendron decoration degree10.1039/C5RA12177A ↗
34. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions10.1517/17425247.2011.553216 ↗
35. Stepwise pH-sensitive and biodegradable polypeptide hybrid micelles for enhanced cellular internalization and efficient nuclear drug delivery10.1016/j.colsurfb.2019.05.071 ↗
36. Development of novel cationic chitosan-and anionic alginate-coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol
37. Effects of particle hydrophobicity, surface charge, media pH value and complexation with human serum albumin on drug release behavior of mitoxantrone-loaded pullulan nanoparticles10.3390/nano6010002 ↗
38. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin10.1016/j.carbpol.2011.01.037 ↗
39. Surface charge switchable and pH-responsive chitosan/polymer core-shell composite nanoparticles for drug delivery application10.1016/j.compositesb.2017.03.028 ↗
40. Polyelectrolyte complexes of carboxymethyl chitosan/alginate based drug carrier for targeted and controlled release of dual drug10.1016/j.jddst.2019.03.036 ↗
41. Co-encapsulation of dual drug loaded in MLNPs: implication on sustaineddrug release and effectively inducing apoptosis in oral carcinoma cells10.1016/j.biopha.2018.05.096 ↗
42. Tunable decoupling of dual drug release of oppositely charged, stimuli-responsive anisotropic nanoparticles10.1021/acsami.9b15485 ↗
43. Polyplexes for gene and nucleic acid delivery: Progress and bottlenecks10.1016/j.ejps.2020.105358 ↗
44. Research highlights: investigating the role of nanoparticle surface charge in nano-bio interactions10.1039/C7EN90014G ↗
45. Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review10.1080/08982104.2019.1652645 ↗
46. Mechanistic understanding of nanoparticles’ interactions with extracellular matrix: the cell and immune system10.1186/s12989-017-0199-z ↗
47. Apoptotic lysosomal proton sponge effect in tumor tissue by cationic gold nanorods10.1039/C9NR04323C ↗
48. The proton sponge hypothesis: fable or fact?10.1016/j.ejpb.2018.05.034 ↗
49. In vitro cytotoxicity and transfection efficiency of pdna encoded p53 gene-loaded chitosan-sodium deoxycholate nanoparticles10.2147/IJN.S205324 ↗
50. Design, synthesis, and in vitro evaluation of low molecular weight protamine (LMWP)-based amphiphilic conjugates as gene delivery carriers10.1208/s12249-018-1235-5 ↗
51. Non-viral in vitro gene delivery: it is now time to set the bar!10.3390/pharmaceutics12020183 ↗
52. Effect of chemical composition and state of the surface on the toxic response to high aspect ratio nanomaterials10.2217/nnm.11.80 ↗
53. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles10.1016/j.jconrel.2013.09.013 ↗
54. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
55. The effect of surface charge on cellular uptake and inflammatory behavior of carbon dots10.1016/j.colcom.2020.100243 ↗
56. Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells10.1186/1743-8977-7-25 ↗
57. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages10.1016/j.jconrel.2010.11.019 ↗
58. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake10.1021/ja2084338 ↗
59. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery10.1182/blood-2006-03-012534 ↗
60. Macrophage-targeted nanoparticle delivery systems
61. Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake10.1021/acsnano.7b06995 ↗
62. Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis10.1016/j.biomaterials.2015.05.028 ↗
63. Neutrophils, as “Trojan horses”, participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect10.1080/10717544.2019.1701141 ↗
64. Stealth surface driven accumulation of “Trojan Horse” for tumor hypoxia relief in combination with targeted cancer therapy10.1016/j.cej.2019.122252 ↗
65. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma10.18632/oncotarget.9464 ↗
66. Surface charge-dependent cellular uptake of polystyrene nanoparticles10.3390/nano8121028 ↗
67. Multifunctional nanosystems at the interface of physical and life sciences10.1016/j.nantod.2008.10.013 ↗
68. Targeted drug delivery systems: strategies and challenges
69. Multifunctional nanomedicines: potentials and prospects10.1007/s13346-012-0123-x ↗
70. Effect of partial PEGylation on particle uptake by macrophages10.1039/C6NR07353K ↗
71. Pharmacokinetics and biodistribution of nanoparticles
72. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating10.1016/S0378-5173(02)00129-1 ↗
73. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles10.1016/j.biomaterials.2011.01.021 ↗
74. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density10.1023/A:1012248721523 ↗
75. Cloaking nanoparticles with protein corona shield for targeted drug delivery10.1038/s41467-018-06979-4 ↗
76. No king without a crown-impact of the nanomaterial-protein corona on nanobiomedicine10.2217/nnm.14.184 ↗
77. The Crown and the Scepter: roles of the protein corona in nanomedicine10.1002/adma.201805740 ↗
78. Formation of a protein corona influences the biological identity of nanomaterials10.1016/j.rpor.2018.05.005 ↗
79. Understanding the chemical nature of nanoparticle-protein interactions10.1021/acs.bioconjchem.9b00348 ↗
80. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment10.1039/C1CS15233E ↗
81. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis10.1093/infdis/jiu396 ↗
82. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system10.1016/j.biomaterials.2013.07.102 ↗
83. Effect of surface charge and hydrophobicity on phospholipid-nanoparticle corona formation: a molecular dynamics simulation study10.1016/j.colcom.2018.04.008 ↗
84. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface10.1016/j.colsurfb.2014.09.009 ↗
85. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery10.1021/la401192x ↗
86. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration10.1016/j.ijpharm.2006.10.029 ↗
87. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W ↗
88. Protein corona: a new approach for nanomedicine design10.2147/IJN.S129300 ↗
89. Proteins: emerging carrier for delivery of cancer therapeutics10.1517/17425247.2013.805200 ↗
90. Mazumder · 2019
91. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates10.1016/S0169-409X(03)00108-X ↗
92. PEGylation in anti-cancer therapy: an overview
93. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
94. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B10.1016/j.fitote.2012.02.004 ↗
95. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure10.1016/j.nano.2017.12.003 ↗
96. Physical and chemical profiles of nanoparticles for lymphatic targeting10.1016/j.addr.2019.09.005 ↗
97. Enhanced lymphatic uptake of leflunomide loaded nanolipid carrier via chylomicron formation for the treatment of rheumatoid arthritis10.15171/apb.2018.030 ↗
98. Crossing the intestinal barrier via Listeria adhesion protein and Internalin A10.1016/j.tim.2018.12.007 ↗
99. Fate and translocation of (nano)particulate matter in the gastrointestinal tract10.1007/978-3-030-12461-8_12 ↗
100. Overview of the advantages and disadvantages of different mucosal sites for the delivery of nanoparticles10.1007/978-3-030-35910-2_3 ↗